µ À z } v ] & µ v v v ] / v l - acmt · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro...
TRANSCRIPT
![Page 1: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/1.jpg)
Acute vs Chronic Frequent Cannabis IntakeACMT Seminars in Forensic Toxicology December 9, 2015Professor Dr. Dr. (h.c.) Marilyn A. HuestisChief, Chemistry & Drug Metabolism, IRPNational Institute on Drug Abuse, NIH
![Page 2: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/2.jpg)
Cannabinoid Pharmacokinetics
![Page 3: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/3.jpg)
Plasma PharmacokineticsAfter Acute Smoked Cannabis
![Page 4: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/4.jpg)
Absorption: Inhalation• Highly efficient route of drug delivery to the brain, similar to iv route • Rapid onset of effects due to speed of drug delivery to the brain• Effective drug delivery contributes to high abuse liability of smoked drugs
![Page 5: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/5.jpg)
THC, 11-OH-THC & THCCOOH Plasma Concentrations After Single THC Cigarette180150120
906030
0-2 2 6 10 14 18 22
THCµg/L
Minutes
THC11-OH THCTHCCOOHInhaleN = 6
3.55% THC
![Page 6: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/6.jpg)
Absorption: Inhalation• Rapid, peak occurs during smoking• Systemic availability 18 - 50%• Smoking dynamics important: # puffs, duration
& volume of inhalation, hold time, time between puffs, smoking time, experience of smoker
• Individuals titrate their smoked or vaporized dose• THC disposition attributed to 1° & 2° tissue distribution, metabolism & excretion
![Page 7: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/7.jpg)
Inter-subject Variability in Plasma Concentrations
µg/L
0
100
200
300
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
Subject BSubject CSubject ESubject FSubject GSubject H
HoursSmoking
3.55% THC
![Page 8: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/8.jpg)
Cannabinoid Metabolism∆9-Tetrahydrocannabinol
(THC)
11-hydroxy-THC(11-OH-THC)
11-nor-9-carboxy-THC(THCCOOH)
Glucuronidation
Cannabinol (CBN)
Cannabidiol (CBD)
CYP 2C9CYP 2C19CYP 2D6
Alcohol dehydrogenase ormicrosomal alcohol oxygenase
& aldehyde oxygenase
UGT 1A3UGT 1A1
UGT 1A9UGT 1A10
UGT 1A9UGT 1A10
![Page 9: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/9.jpg)
Chronic Daily Cannabis SmokersAfter Acute ExposureUrinary Cannabinoid Excretion in Occasional Cannabis Smokers
![Page 10: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/10.jpg)
Excretion• Urine excretion ≈ 15-30%, fecal 27-65%• Calculated half-lives affected by sampling time, assay sensitivity & specificity, frequency of use • Plasma THC t 1/2 estimates range from 20 h to 12 d, best estimate ≈ 4.3 days• Urine THCCOOH t 1/2 best estimate ≈ 3.0 days
![Page 11: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/11.jpg)
Urinary THCCOOH ExcretionAmt Remaining to be Excreted Method
t 1/2 = 29.9 hr = 0.92
2.53.03.54.04.55.05.5
0 24 48 72 96 120 144 168Hours
199.7 µg excreted in 7 d0.54% of 33.8 mg THC dose
Subject B 3.55% THC
![Page 12: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/12.jpg)
Urinary Cannabinoid Excretion• Common assumption that cannabinoids positive in
urine for weeks after last use• Huestis et al 1995 J Anal Toxicology
– Acute smoked THC (1.75; 3.55%)– Collected all specimens for 21 days– EMIT immunoassay last positive test
• 50 ng/mL 1 - 2 days– GCMS
• 15 ng/mL up to 5 days
![Page 13: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/13.jpg)
Differentiating New Cannabis Use From Residual Cannabinoid Excretion in Less than Daily Cannabis Smokers: Creatinine-Normalized Urine THCCOOH Concentrations
![Page 14: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/14.jpg)
Detecting New Cannabis Use in Occasional Smokers• Urine THCCOOH concentrations in 2 specimens collected at known times• Was cannabis smoked between collections?• Frequent problem faced by:
– Drug treatment programs– Drug courts– Workplace drug testing program– Parole officers– Military commanders
![Page 15: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/15.jpg)
Calculation of NormalizedTHCCOOH Concentrations:• Urine Cannabinoids = ng/mL• Urine Creatinine = mg/mL• ng/mL = ng Cannabinoids
mg/mL mg Creatinine• Later normalized value divided
by the earlier normalized value
![Page 16: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/16.jpg)
Creatinine Normalization Improves Differentiation of New Cannabinoid Use from Residual Drug Excretion
ng/mg
Hours
ng/mL After controlled administration of 3.55% smoked THC
0255075
100125150
0255075
100125150
0 30 60 90 120 150 180
THCCOOH/creatinine (ng/mg)THCCOOH (ng/mL)
![Page 17: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/17.jpg)
Differentiating New Drug Use from Residual Drug Excretion• Normalized ratio ≥ 1.5 • Current prediction accuracy: 74.2% • Sensitivity: 33.4% Specificity: 99.8%• FP: 0.1% FN: 27.0% • Normalized ratio ≥ 0.5• Best prediction accuracy: 85.4%• Sensitivity: 80.1% Specificity: 90.2%• FP: 5.6% FN: 8.6%
![Page 18: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/18.jpg)
Actual Case• Urine collections:
Time THCCOOH Creatinine NormalizedDate/h ng/mL mg/dL ng/mg
9 Aug/1300 273 135 20213 Aug/0800 86 31.6 272
• New use indicated by pattern of excretion profile• If punitive outcome: U2/U1 must be >1.5 • Individual’s U2/U1 = 1.34
![Page 19: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/19.jpg)
Actual Case: Findings• Prosecution position: new use was indicated by
pattern of excretion profile• Defense position: U2/U1 must be >1.5 to prove
new use beyond reasonable doubt. • Accused U2/U1 = 1.34• Accused acquitted of multiple uses of cannabis• Guilty of single use
![Page 20: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/20.jpg)
New Model To Predict New Use• Smith et al, J Anal Toxicol 2009• Creatinine normalized urine pairs segregated by time interval between collection
– 0 - 24 h– 24 - 48h– 48 - 72h– 72 - 96h– > 96h
• U2/U1 calculated• Compare to minimum, median & maximum ratio for the specific timeframe between urine collections
![Page 21: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/21.jpg)
Minimum, Median & Maximum Ratios for each 24 h Interval with Urine THCCOOH ≥15 µg/L
00.5
11.5
22.5
33.5
0-24 24-48 48-72 72-96 96+
Min Median Max
U2/U1
Time Interval between U2 & U1 (h)
![Page 22: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/22.jpg)
Actual Case: Findings• This individual with urine cannabinoids/creatinine concentrations >200 ng/mg • 91 h between urine specimen collections & U2/U1 ratio 1.34• Max ratio for 72-96 h 0.3; highly likely smoked cannabis between U1 & U2• New U2/U1 ratio ranges for intervals between urine specimens improves differentiation of new cannabis use & residual urinary excretion of THCCOOH
![Page 23: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/23.jpg)
Blood & Plasma Cannabinoids in Chronic Frequent Cannabis Smokers
![Page 24: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/24.jpg)
Chronic Daily Cannabis SmokersAfter Acute ExposureChronic Frequent Cannabis Smokers Cannabinoid Concentrations in Blood & Plasma After Acute Smoked Cannabis
![Page 25: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/25.jpg)
Smoked Cannabis Study• Smoked 6.8 % THC cannabis cigarette ~ 54 mg
![Page 26: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/26.jpg)
1st blood10 min
after smoking1st blood = 10 min
![Page 27: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/27.jpg)
Markers of Recent Cannabis Smoking in Blood
![Page 28: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/28.jpg)
Chronic Daily Cannabis SmokersAfter Acute ExposureOccasional (N=10) & Chronic (N=10) Daily Cannabis Smokers Cannabinoid Concentrations in Blood After Acute Smoked Cannabis
![Page 29: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/29.jpg)
Median Blood THC
![Page 30: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/30.jpg)
Median Blood THCCOOH
![Page 31: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/31.jpg)
Median Blood THCCOOH-glucuronide
![Page 32: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/32.jpg)
Time of Last DetectionAnalyte Frequent Smoker (h) Occasional Smoker (h) Significant?
THC >30 (24.0->30) 4.0 (1.0-6.0) Y11-OH-THC 12.0 (3.1->30) 3.0 (1.0-5.0) YTHCCOOH >30 >30 N
CBD 0 (0-0.5) 0 NCBN 0.6 (0-2.1) 0 (0-1.1) Y
THC-glucuronide 0 (0-0.5) 0 (0-0.6) NTHCCOOH-glucuronide >30 27.0 (0->30) Y
![Page 33: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/33.jpg)
Cannabinoids in Blood of Chronic
Frequent Cannabis Smokers During
Sustained Abstinence?
![Page 34: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/34.jpg)
Participants• IRB approved, written informed consent• 28 subjects, 19 - 38 yrs, 50% male, 82.1% AA• Continuously resided on closed clinical unit • Whole blood collected upon admission & each 24 h
thereafter for 7 days• 12.8 ± 9.1 jts or blunts/day (2 – 40)
![Page 35: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/35.jpg)
Whole Blood THC in 28 Frequent Cannabis SmokersDay N
≥ 0.25 µg/L% N
≥ 1 µg/L%
1 15 53.6 4 14.32 14 50.0 3 10.73 12 42.9 2 7.14 9 32.1 3 10.75 11 39.3 2 7.16 10 35.7 3 10.77 6 21.4 3 10.7
![Page 36: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/36.jpg)
µg/L
Day
Whole Blood THC Positive All 7 Days
![Page 37: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/37.jpg)
Participant Demographics for Whole Blood THC Positive All 7 DaysSubject Self report J or B/day Days used past 14 days BMI Gender
A 20 14 24.4 FB 7 11 26.6 FC 8 3 22.8 FD 32 14 39.0 FE 16 14 32.0 F
![Page 38: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/38.jpg)
Chronic Daily Cannabis Smokers• Mean age 27.4±6.6 years (19–43)• Mean BMI 23.8±3.8 (16.4-32.8)• Mean cannabis joints/day 10.6±6.3 (1–30)• Mean years cannabis use 10.6±5.8 (4-28)• 1 subject ≥2 µg/L for 18 d & ≥1 µg/L for 30 d• THC detected in 3 of 5 specimens on day 30 (up to
1.3 µg/L)
![Page 39: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/39.jpg)
Whole Blood Detection Rates for THC, 11-OH-THC & THCCOOH (0.5 ng/mL) in Chronic Daily Cannabis Smokers During 30 Days Sustained Abstinence
![Page 40: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/40.jpg)
Round the Clock 20 mg Oral Synthetic THC/Marinol®• Synthetic THC in sesame oil• FDA-approved medication for nausea & vomiting with cancer chemotherapy & HIV-wasting disease
![Page 41: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/41.jpg)
Around-the-Clock 20 mg Oral THC• Investigate THC & metabolite disposition in plasma
during around-the-clock oral THC in chronic cannabis smokers– After smoked cannabis self-administration– Single-dose oral THC (dronabinol) pharmacokinetics– During continuous dosing – During monitored abstinence
• Evaluate tolerance development & model daily therapeutic & recreational THC intake
![Page 42: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/42.jpg)
Study Design• Institutional Review Board-approved study &
written informed consent• Subjects 10• Dosing 9 days 37 oral 20 mg THC doses
Escalating 40-120 mg THC/day• # Collections 36/subject• Cannabis use 7.9 ± 8.0 (1 – 24 joints/day)• Last cannabis use 0.7 ± 0.5 days (0 – 1)• Lifetime use 10 ± 4.7 years (4 – 18)
![Page 43: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/43.jpg)
Cannabinoid Results in Plasma & OFN = 360 Plasma OF
THCµg/L11-OH-THCµg/L THCCOOHµg/L THCµg/L
11-OH-THCµg/L THCCOOHng/L% Positive 100 99.7 100 21.1 - 98.3
Range 1.2 -67.6 0.6 - 38.9 13.3 -497.9 0.5 -399.2 - 7.5 -1087.7Median Cmax 34.6 7.3 269.1 6.5 - 361.6Median Tmax (h) 103.5 149.5 161.0 -18.0 - 161.0
![Page 44: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/44.jpg)
Plasma & OF THC ResultsTHC Plasma µg/L OF µg/L
Median Range Median RangeAdmission n = 10 5.2 2.4 - 33.3 3.3 ND - 399.2Pre-dose n = 30 3.6 1.5 - 33.3 2.1 ND - 399.21st dose n = 50 6.8 2.3 - 27.7 0.7 ND - 6.8
Days 2 - 4 (100 mg/d)n = 90 9.7 3.3 - 44.4 0.0 ND - 8.0Days 5 - 7 (120 mg/d) n = 90 10.8 4.2 - 67.6 0.0 ND - 1.1After last dose n = 80 5.3 1.2 - 31.3 ND NDAt discharge n = 10 3.2 1.2 - 5.2 ND ND
![Page 45: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/45.jpg)
Breath Cannabinoid Concentrations After Acute Cannabis Smoking in Occasional & Chronic Frequent Smokers
![Page 46: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/46.jpg)
THC-Positive Breath SpecimensTime after
smoking (h)Chronic Users
N=13Occasional Users
N=11Admission 15.4% 0
-1.0 0 00.5 100% 90.9%1.0 76.9% 63.6%2.0 53.8% 03.0 0 04.0 7.7% 0
![Page 47: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/47.jpg)
THC Excretion in Weekly Sweat Patches in Chronic Daily Cannabis Smokers During Abstinence
![Page 48: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/48.jpg)
What Is Best THC Blood Concentration To Indicate Driving Impairment?1, 2 or 5 µg/L?
Desrosiers et al 2014 Clinical Chemistry
![Page 49: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/49.jpg)
Median % Positive Samples Blood THC 1 µg/L
![Page 50: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/50.jpg)
Median % Positive Samples Blood THC 5 µg/L
![Page 51: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/51.jpg)
Legal Limits for Blood THC Concentrations & Driving • In our research, occasional use = less than daily smoking & frequent smoking as daily cannabis smoking (varies by author)• WA state uses ≥ 5 µg/L THC cutoff; CO inference of impairment at ≥ 5 µg/L THC • Only 81.2% occasional smokers ≥ 5 µg/L at 30 min; all < 5 µg/L by 2 h• <20% frequent smokers ≥ 5 µg/L by 5 h; 16.7% still ≥ 5 µg/L after 30 h
![Page 52: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/52.jpg)
Median Time of Last Detection in BloodAnalyte Frequent Smoker (h) Occasional Smoker (h) Significant?
THC (1 µg/L) >30 (24.0->30) 4.0 (1.0-6.0) YTHC (5 µg/L) 3.5 h (1.1->30 h) 1.0 h (0-2.1 h)* Y
11-OH-THC (1 µg/L) 12.0 (3.1->30) 3.0 (1.0-5.0) YTHCCOOH (1 µg/L) >30 >30 N
CBD (1 µg/L) 0 (0-0.5) 0 NCBN (1 µg/L) 0.6 (0-2.1) 0 (0-1.1) Y
THC-glucuronide (0.5) 0 (0-0.5) 0 (0-0.6) NTHCCOOH-glucuronide (5 µg/L) >30 27.0 (0->30) YTwo occasional smokers never had THC≥ 5µg/L
![Page 53: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/53.jpg)
Urinary THCCOOH Excretion in Chronic Daily Cannabis Smokers
![Page 54: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/54.jpg)
Cannabinoid Excretion Daily Use• 22 frequent cannabis users resided on closed
research unit under medical supervision• Urine cannabinoids screen >100 ng/mL on
admission• All urine specimens collected individually
ad libitum for up to 30 days• 50 ng/mL immunoassay; 15 ng/mL GCMS for
THCCOOH
![Page 55: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/55.jpg)
Urinary THCCOOH Excretion in Chronic Daily Cannabis SmokersN AgeMeanSD
BMIMeanSDJts/DayMedian 1st Use MeanSD
YrsUsedMeanSDM 12 25.1 ±3.6 25.3 ±3.8 6.03 - 60 16.3 ±3.3 8.6 ±3.9
F 10 25.3 ±3.8 29.5 ±6.8 7.51 - 30 16.4 ±3.4 9.4 ±5.2
![Page 56: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/56.jpg)
Urinary THCCOOH Excretion in Chronic Daily Cannabis SmokersN Days on UnitMeanSD
THCCOOH ng/mgMedianRange
Ist NegDaysMeanSD
Last PosDaysMeanSD
Last Posng/mgMeanSDM 12 26.3 ±3.9 28331 - 563 10.33.9 -17.2
20.5 ±6.3 6.53 - 26
F 10 27.6 ±3.3 17156 -793 9.1 2.2 –23.126.3 ±3.3 10.55 - 49
![Page 57: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/57.jpg)
Daily Cannabis SmokersUrinary Excretion• 50% highest THCCOOH occurred in 1st urine• 50% Cmax up to 30 h after admission• No significant BMI difference for M or F• Mean±SD (range) time to last positive urine
– Males 491.2 ± 150.3 h (289.2 - 716.2)– Females 632.3 ± 79.6 h (498.7 - 716.0)
• Significantly longer urinary cannabinoid excretion rate in females (p<0.05)
![Page 58: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/58.jpg)
Mean Detection Rates After 1st Negative THCCOOH in Urine
0
20
40
60
80
100
0 5 10 15 20 25 30Days After 1st Negative 50 µg/L Screen
Detec
tion Ra
te (%)
>150 ng/mg51 – 150 ng/mg0 – 50 ng/mg
![Page 59: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/59.jpg)
Does Presence of THC &/or 11-OH-THC in Urine Suggest Recent Cannabis Use As Suggested by Kemp et al 1992, Manno et al 2001 & Brenneisen 2009
![Page 60: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/60.jpg)
0
25
50
75
100
125
µg/L
-2 8 18 28 38 48 58 68 78 88Hours
THC11-OH-THCTHCCOOH
THC & Metabolite Urinary Excretion After One 2.74% THC Cigarette
![Page 61: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/61.jpg)
Frequent Cannabis Exposure Study• IRB-approved; written informed consent• 33 subjects resided on closed research unit• All urine specimens individually collected for 30 days• Tandem E. coli ß-glucuronidase & alkaline hydrolysis
for THC, 11-OH-THC & THCCOOH in urine• All specimens quantified for 1st 3 days• Urinary THC <2.5 µg/L within 72 h of drug abstinence
in 26/33 (78%) daily smokers• 7 frequent users urine analyzed by 2D-GCMS• Testing stopped when THC <LOQ in 3 consecutive voids
![Page 62: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/62.jpg)
Urine THC Concentrations
![Page 63: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/63.jpg)
Relevance1st data on extended urinary excretion of THC,
11-OH-THC & THCCOOH in frequent cannabis users during monitored abstinenceTHC was detected in urine for up to 25 days after
tandem enzymatic & alkaline hydrolysisNeither THC or 11-OH-THC in urine are definitive
markers of recent cannabis use
![Page 64: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/64.jpg)
Predicting New Cannabis Use in Urine Chronic Daily Cannabis Smokers
![Page 65: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/65.jpg)
Model Development & Validation• Develop & validate a model to differentiate new cannabis use from residual urinary drug excretion in chronic daily cannabis smokers• Significance
– Extended excretion of cannabinoids in urine after chronic usage– No models developed or validated for chronic cannabis smokers
• All urine collected, cannabinoids quantified & normalized to creatinine concentrations
![Page 66: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/66.jpg)
Model Development• 48 Participants resided on closed research unit throughout to preclude cannabis use• 2,377 urine specimens collected• For each subject, every specimen compared with every other specimen collected ≥48h later• 123,513 Specimen 2/Specimen 1 ratios• Ratios sorted into Specimen 1 groups: 6-15, 15-25, 25-50, 50-100, 100-200, 200-400, 400-600, >600 ng/mg
![Page 67: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/67.jpg)
Model Development• Unique model for each Specimen 1 group• Prediction probabilities 80, 90, 95, 99%• Models developed for creatinine-normalized concentration ratios• Non-normalized ratio models abandoned
– Large variability– Less accurate predictions than creatinine-normalized models
![Page 68: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/68.jpg)
Model Development
80% PI90% PI95% PI99% PI
7203600
Ratio
ΔT (≥48 H)
Single Specimen 1 GroupUpper PI Limit = Ae-kt + Z1-/2 S2Model + RMS√
![Page 69: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/69.jpg)
Decision Rules: Rule 1• Increasing THCCOOH after admission
– Peak concentrations up to 40 h after admission– Represents cannabis use close to admission– Occurred in 6 participants (9%)– Ratios expected to be high
• Rule 1: Cannabis re-use predicted from 1st & 2nd specimens = do not use 1st specimen for predictions
![Page 70: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/70.jpg)
Decision Rules: Rule 2• Admission specimen >800 ng/mg, remaining >200 ng/mg for up to 14 days• Occurred in 4 participants (6%)• Rule 2: If 1st specimen ≥800 ng/mg, & ≥200 ng/mg on day 5, false re-use predictions may occur up to 14 days
![Page 71: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/71.jpg)
Decision Tree
New use predicted:False prediction possible for 14 days (Rule 2). Collect again after 15 days
Collect 2nd specimen on 5th dayCollect 2nd specimen ≥48h later
1st Specimen <800 ng/mg
Collect 1st Specimen
No new use predicted:Use 1st specimen for all comparisonsNew use predicted:Do not use 1stspecimen (Rule 1). Collect 3rdspecimen at least 48h later.
1st Specimen ≥800 ng/mg
<200 ng/mg:Model prediction accurate
≥200 ng/mg:
No new use predicted:Model prediction accurate
![Page 72: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/72.jpg)
Suspected Cannabis Re-use
00.20.40.60.8
11.21.41.6
0 100 200 300 400 500 600
New use participant
Days
NN (ng/mL)CN (ng/mg)
Concen
tration
Ratio
ΔT
Specimen 1 group 200-400 ng/mg0
500100015002000
0 5 10 15 20 25 30
![Page 73: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/73.jpg)
0
0.5
1
0 200 400 600
Ratio
Specimen 1 group 200-400 ng/mg
ΔT hours
Remaining 67 Participants
![Page 74: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/74.jpg)
Model of Recent Cannabis Smoking Based on Urine THC-glucuronide (Desrosiers 2014 Clin Chem)• If urinary THC-glucuronide increase
– Absolute % difference ≥50% between 2 consecutive THC-glucuronide-positive samples – Creatinine-normalized concentration ≥ 2 µg/g in 1st
sample • Predicted cannabis smoking within 6 h of 1st urine sample with high efficiencies
– 93.1% in frequent smokers– 76.9% in occasional smokers
![Page 75: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/75.jpg)
Subjective “High”
![Page 76: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/76.jpg)
Dose & Tolerance Effects
D’Souza, Neuropsychopharmacology, 2008
Placebo NonabuserPlacebo Abuser
2.5 mg Nonabuser2.5 mg Abuser
5 mg Nonabuser5 mg Abuser
Total Immediate Recall Delayed Free Recall
Total Co
rrect Ite
ms Rec
alled
![Page 77: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/77.jpg)
Hysteresis• Acute cannabis effects have counter-clockwise hysteresis indicating prominent distribution phase• After blood/tissue equilibrium (~ 45min), correlation of THCconcentrations & effects, e.g., tracking up to 7 h• Rarely is blood sampled in accident or DUID prior to distribution
![Page 78: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/78.jpg)
Concentration Effect Curves
100
THC µg/L
BPM120
140
80
20015010050060
.15 h.25 h
.05 h
.10 h.79 h
12 h
6 h
VAS Feel Drug
20015010050001020304050
.20 h.38 h
.07 h
.15 h.79 h
Heart Rate
![Page 79: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/79.jpg)
Hysteresis in Subjective “High”
![Page 80: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/80.jpg)
Long-term Neurocognitive Impairment in
Chronic Cannabis Smokers?
![Page 81: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/81.jpg)
Public Health & Safety Implications• Some states have zero tolerance or per se
legislation for cannabinoids in blood, plasma/serum or urine for driving under the influence of drugs
• Long-term cannabinoid excretion makes interpretation of cannabinoid involvement in accidents or crimes difficult
• Is there residual cognitive &/or psychomotor impairment with residual THC concentrations?
![Page 82: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/82.jpg)
[18F]FMPEP-d2: inverse agonist radioligand for cannabinoid CB1 receptors, collaboration with NIMH, Bob Innes & Jussi Hirvonen
Reversible & Regionally Selective Downregulation of Brain Cannabinoid CB1Receptors in Chronic Daily Cannabis Smokers
![Page 83: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/83.jpg)
Study Design & Subjects• [18F]FMPEP-d2 PET in cannabis users & healthy male subjects• Repeat [18F]FMPEP-d2 PET in cannabis users after 28 days monitored abstinence
Healthy Subjects Cannabis SmokersN 26 26
Age (yrs) 22 ± 10 29 ± 8BMI (kg/m2 27 ± 5 24 ± 4
Cannabis use <10X life 12 ± 8 yrs; 10 ± 7 jts/d
![Page 84: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/84.jpg)
CB1-Cannabinoid Receptors Specifically Downregulated in Cortical Regions of Chronic Daily Cannabis Smokers (N=30) as Compared to Controls (N=28)Healthy subjects Chronic cannabis smokers
Group × region interaction: F=6.5, p=0.0001 * p < 0.05 ** p < 0.005Brain Region
![Page 85: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/85.jpg)
CB1 Receptor DownregulationCorrelated with Years of Cannabis AbuseControl subjects: no correlation with age
![Page 86: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/86.jpg)
CB1 Receptors Increase after Abstinence in Specific Brain Regions
Repetition × region interaction: F=3.3, p=0.037* p < 0.05
![Page 87: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/87.jpg)
Does Cognitive Impairment Accompany Low Residual THC Concentrations in Chronic Frequent Cannabis Smokers?
![Page 88: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/88.jpg)
Public Health & Safety Implications• Frequent cannabis exposure can produce neurocognitive impairment
– Solowij et al 1995: irreversible loss of cognitive performance in heaviest cannabis users– Pope et al 2001: impairment at least 7 but less than 28 days of abstinence in heavy users– Bolla et al 2002: dose-related cannabis impairment >28 days of abstinence
• Frequent cannabis smokers store THC in tissues, with increasing body burden with frequency & duration of use
![Page 89: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/89.jpg)
Dunedin NZ Study• 1037 individuals followed from age 13 to 38• Cannabis use evaluated by interviews at 18, 21, 26, 32 & 38 years• Neuropsychological testing conducted at ages 13 & 38, before & after a pattern of persistent cannabis use developed• # occasions cannabis smoking ages 14-21 documented from never to >400 times• Later life outcomes dose-dependently varied withcannabis use frequency & age of 1st drug use
![Page 90: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/90.jpg)
0 20 40 60 80Welfare
Unemployed
Income
Degree
Never1-99100-199200-299300-399400+
Cannabis Use & Later Life Outcomes Are Dose-Dependent
# occasions smokingcannabis
ages 14-21
% University degree age 25Personal income NZ $age 25%Unemployed (ages 21-25)% Welfare dependent(ages 21-25)
(Fergusson & Boden Addiction 2008)
![Page 91: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/91.jpg)
Neuropsychological Decline from Childhood to Midlife with Persistent Cannabis Use• Meier et al 2012 Proc Nat Acad Sci
– Dunedin Study: 1037 individuals birth to 38 yrs– Reported neurotoxic cannabis effects on adolescent brain with persistent cannabis intake– Decline in function in multiple domains– Impairment strongest in adolescent-onset cannabis users, more persistent use greater decline in IQ– Cannabis cessation did not fully restore functioning among adolescent-onset cannabis users– Prevention & policy efforts should target adolescents
![Page 92: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/92.jpg)
IQ tested ages 13 & 38; Meier MH et al., PNAS 2012
Neuropsychological Decline from Childhood to Midlife with Persistent Cannabis Use1 Diagnosis 2 Diagnoses 3+ Diagnoses
-0.8
-0.6
-0.4
-0.2
0
0.2
Change
in Full-
Scale IQ
(in
standar
d devia
tion un
its)
p = 0.44 p = 0.09 p = 0.02
Cannabis dependent before age 18Not cannabisdependent before age 18
![Page 93: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/93.jpg)
Psychomotor Impairment & Chronic Frequent Cannabis Smoking
PLoS One 2012
![Page 94: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/94.jpg)
Public Health & Safety Implications• Some states have zero tolerance or per se
legislation for cannabinoids in blood, plasma/serum or urine for driving under the influence of drugs
• Long-term cannabinoid excretion makes interpretation of cannabinoid involvement in accidents or crimes difficult
• Is there residual cognitive &/or psychomotor impairment with residual THC concentrations?
![Page 95: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/95.jpg)
Psychomotor Impairment in Chronic Daily Cannabis Smokers • What is duration of psychomotor impairment in
chronic frequent cannabis smokers?• Compared psychomotor performance on tasks
validated by Jan Ramaekers at University of Maastricht to predict impaired on the road driving
• Compared performance of chronic frequent smokers to occasional cannabis & ecstasy users over 22 days
![Page 96: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/96.jpg)
Psychomotor Tasks• Critical tracking
– Measures ability to control a displayed error signal in a 1st-order compensatory tracking task
– Primary dependent measure is frequency of control losses or critical frequency (λc)
• Tracking error during divided attention– Ability to divide attention between two tasks performed
simultaneously– Primary dependent measure is control losses & tracking
![Page 97: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/97.jpg)
Divided Attention Task (DAT)• Control Losses
– # times cursor hits side marker• Mean Tracking Error
– Distance between cursor’s position & center of scale• “Hits”
– # of correct “2” detections• False alarms
– # of incorrect “2” detections• Reaction time
– Time to “2” detection (in msec)
![Page 98: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/98.jpg)
Mean SE Critical Tracking Task in Chronic Cannabis Smokers During Sustained Abstinence
012345
BL D 8 D 14-16 D 21-23 Control
* * **
![Page 99: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/99.jpg)
Mean±SE Tracking Error (mm) in Chronic Daily Cannabis Smokers During Sustained Abstinence
05
10152025
BL D 8 D 14-16 D 21-23 Control
* * ** # #
![Page 100: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/100.jpg)
Mean±SE DAT Control Losses in Chronic Cannabis Smokers During Sustained Cannabis Abstinence
05
101520253035
BL D 8 D 14-16 D 21-23 Control
*
**
*#
![Page 101: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/101.jpg)
Psychomotor Impairment in Chronic Cannabis Smokers• Psychomotor performance in critical tracking &
divided attention tasks in 19 male chronic, daily cannabis smokers impaired at baseline relative to occasional drug users
• Sustained cannabis abstinence moderately improved critical tracking & divided attention performance, but impairment still observable after 3 weeks of abstinence
![Page 102: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/102.jpg)
Psychomotor Impairment in Chronic Cannabis Smokers• We reported significant increases in CB-1
cannabinoid receptors in specific brain areas during improvement in psychomotor performance
• Chronic daily cannabis smokers had impaired psychomotor function compared to occasional drug users for at least 3 weeks of sustained cannabis abstinence
![Page 103: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/103.jpg)
KarlScheidweiler, PhD MadelineSwortwood, PhD
Xingxing Daio, PhD
Osama Abulseoud, MD
Maria Andersson, PhD Jeremy Charlier, PhD
Allan Barnes, BS
Rebecca Hartman, PhD
![Page 104: µ À Z } v ] & µ v v v ] / v l - ACMT · &dqqdelqrlg 0hwderolvp ¨ 7hwudk\gurfdqqdelqro 7+& k\gur[\ 7+& 2+ 7+& qru fduer[\ 7+& 7+&&22+ *oxfxurqlgdwlrq &dqqdelqro &%1 &dqqdelglro](https://reader033.vdocuments.site/reader033/viewer/2022042403/5f16574639e25118cf6e3f1b/html5/thumbnails/104.jpg)
Matt Newmeyer, BS
Megan Taylor, BS Caitlin House, BS
Kayla Ellefson, MS Alex San Nicolas, MS CristinaSempio, MS
Maria LauraZuccoli, MD Jackie Highland, BS